Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Share-based Compensation (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Share-based Compensation for 4 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation changed 0.3% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.4 million, a 8.03% decrease, with the full-year FY2025 number at $44.4 million, down 8.03% from a year prior.
  • Share-based Compensation was $11.1 million for Q4 2025 at Day One Biopharmaceuticals, up from $9.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.0 million in Q2 2024 to a low of $5.6 million in Q2 2022.
  • A 4-year average of $10.0 million and a median of $10.2 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 68.3% in 2023, then fell 17.25% in 2025.
  • Day One Biopharmaceuticals' Share-based Compensation stood at $6.8 million in 2022, then skyrocketed by 58.22% to $10.8 million in 2023, then rose by 2.07% to $11.0 million in 2024, then increased by 0.3% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Share-based Compensation are $11.1 million (Q4 2025), $9.6 million (Q3 2025), and $10.9 million (Q2 2025).